"PHYSICIANS: Steven C. Buck, DO, FACOI Scott Cole, MD Melinda Dunlap, MD Michael A. Gold, MD A. Dwayne Jenkins, MD M. Byron Jennings, MD Grenville Jones, MD Alan M. Keller, MD, FACP Christopher Manus, MD Ali H. Moussa, MD Connie Nguyen, MD Mark R. Olsen, MD, PhD Daron G. Street, MD, FACOG Charles Strnad, MD Charles Taylor, MD Eric D. Thomas, MD Kevin Weibel, DO, FACP Leslie T. Yonemoto, MD Oklahoma’s largest and most integrated cancer care facility of its kind in the region. Built by the region's largest group of private physicians, we have the most cancer specialists under one roof."

During the past decade, Oklahoma Cancer Specialists and Research Institute-Tulsa conducted 134 clinical trials. In the 10-year time frame, 134 clinical trials started and 144 clinical trials were completed, i.e. on average, 107.5% percent of trials that started reached the finish line to date. In the past 5 years, 40 clinical trials started and 93 clinical trials were completed. i.e. 232.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oklahoma Cancer Specialists and Research Institute-Tulsa" #1 sponsor was "National Cancer Institute (NCI)" with 98 trials, followed by "Gynecologic Oncology Group" with 39 trials sponsored, "SWOG Cancer Research Network" with 22 trials sponsored, "Alliance for Clinical Trials in Oncology" with 14 trials sponsored and "GOG Foundation" with 14 trials sponsored. Other sponsors include 106 different institutions and companies that sponsored additional 62 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma Cancer Specialists and Research Institute-Tulsa" #1 collaborator was "National Cancer Institute (NCI)" with 97 trials as a collaborator, "NRG Oncology" with 46 trials as a collaborator, "Gynecologic Oncology Group" with 9 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 5 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma Cancer Specialists and Research Institute-Tulsa" are "Recurrent Ovarian Carcinoma" (23 trials), "Recurrent Fallopian Tube Carcinoma" (18 trials), "Cervical Adenocarcinoma" (17 trials), "Recurrent Primary Peritoneal Carcinoma" (17 trials) and "Cervical Adenosquamous Carcinoma" (14 trials). Many other conditions were trialed in "Oklahoma Cancer Specialists and Research Institute-Tulsa" in a lesser frequency.

Most popular intervention types in "Oklahoma Cancer Specialists and Research Institute-Tulsa" are "Drug" (247 trials), "Other" (139 trials), "Biological" (78 trials), "Procedure" (49 trials) and "Radiation" (15 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (90 trials), "Quality-of-Life Assessment" (51 trials), "Paclitaxel" (44 trials), "Carboplatin" (35 trials) and "Cisplatin" (30 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma Cancer Specialists and Research Institute-Tulsa" are 162 trials for "All" genders, 122 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Oklahoma Cancer Specialists and Research Institute-Tulsa". undefined are not yet recruiting, 34 are recruiting, 96 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 125 completed trials in Oklahoma Cancer Specialists and Research Institute-Tulsa, 1 suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma Cancer Specialists and Research Institute-Tulsa, 16 "Phase 1" clinical trials were conducted, 147 "Phase 2" clinical trials and 127 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".